Naglazyme (Galsulfase)

Galsulfase is a recombinant form of the human enzyme N‑acetylgalactosamine‑4‑sulfatase. After intravenous infusion, it is taken up by cells and localizes to lysosomes, where it cleaves sulfate groups from dermatan sulfate and chondroitin‑4‑sulfate, restoring normal breakdown of these molecules and decreasing lysosomal storage.

The dosage of Naglazyme is individualized. A qualified prescriber determines the amount and infusion schedule based on the patient’s body weight, disease severity, and clinical response. Exact dosing regimens are not publicly disclosed and should follow the prescribing information provided by the healthcare professional.

Safety data for Naglazyme during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Naglazyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

The primary alternative for MPS VI is elosulfase alfa (Vimizim), another recombinant enzyme. Both aim to replace the deficient sulfatase, but they differ in molecular structure, dosing frequency, and reported infusion‑related reaction profiles. Clinical choice depends on physician assessment of efficacy, safety, patient tolerance, and regulatory availability.

Naglazyme must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If a vial is removed from refrigeration, it should be used within the time frame specified in the product’s labeling to maintain potency.

Naglazyme is given as an intravenous infusion. The infusion is performed by a qualified healthcare professional in a setting equipped to manage potential reactions. Infusion duration, rate, and pre‑medication protocols are determined by the prescriber and may be adjusted based on patient tolerance and clinical response.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, significant liver enzyme elevations indicating hepatic injury, and the development of neutralizing antibodies that can reduce therapeutic effectiveness. Patients should be closely monitored during and after infusion for any signs of these events.

Naglazyme is contraindicated in individuals with a known hypersensitivity to Galsulfase or any component of the formulation. Caution is also advised for patients with severe hepatic impairment or uncontrolled cardiac disease, as the safety profile in these populations has not been fully established.